FOLH1 and prostate carcinoma: Besides68Ga-PSMA-HBED-CC, the preferential use of99mTc-labeled urea-based PSMA inhibitor has received interest as an alternative option to widespread the advantages of PSMA imaging due to a number of prostate cancer patients who are scheduled on PSMA imaging.